Lates News

According to AI Express of Every Economic Daily, Dongguan Securities released a research report on April 21, giving Baosaitu (688796.SH) a "buy" rating. The main reasons for the rating include: 1) the Chinese pre-clinical CRO market continues to grow rapidly; 2) the RenMice platform has built core barriers; 3) the company is a leader in the fully human antibody mouse platform. (Daily Economic News)